Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Horizon Pharma Usa Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the competitive landscape for HORIZON PHARMA USA, and when can generic versions of HORIZON PHARMA USA drugs launch?

HORIZON PHARMA USA has two approved drugs.

There are eighteen US patents protecting HORIZON PHARMA USA drugs.

There are one hundred patent family members on HORIZON PHARMA USA drugs in thirty-eight countries and eight supplementary protection certificates in seven countries.

Summary for Horizon Pharma Usa
International Patents:100
US Patents:18
Patent Litigation for Horizon Pharma Usa: See patent lawsuits for Horizon Pharma Usa

Drugs and US Patents for Horizon Pharma Usa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-002 Apr 30, 2013 RX Yes Yes   Start Trial   Start Trial
Horizon Pharma Usa PROCYSBI cysteamine bitartrate CAPSULE, DELAYED RELEASE;ORAL 203389-002 Apr 30, 2013 RX Yes Yes 9,173,851*PED   Start Trial Y   Start Trial
Horizon Pharma Usa RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 AB RX Yes No 6,677,326   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Paragraph IV (Patent) Challenges for HORIZON PHARMA USA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 1 mg, 2 mg, and 5 mg ➤ Subscribe 2012-11-26

Supplementary Protection Certificates for Horizon Pharma Usa Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1919458 194 50001-2014 Slovakia   Start Trial PRODUCT NAME: MERKAPTAMIN; FIRST REGISTRATION: EU/1/13/861, 20130906
1919458 19/2014 Austria   Start Trial PRODUCT NAME: CYSTEAMIN; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130910
1919458 C300649 Netherlands   Start Trial PRODUCT NAME: CYSTEAMINE; REGISTRATION NO/DATE: EU/1/13/861/001-002 20130906
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.